How do you choose between finerenone and traditional steroidal MRAs for patients with heart failure and mildly reduced or preserved EF, considering recent results showing finerenone's efficacy in reducing heart failure events?

Not only is cost coverage important, with reduced rates for commercial, but not Medicare/Medicaid pts, but the expected reduced adverse drug effect profile of finerenone over spironolactone or eplerenone. That is relevant when treating men with borderline hyperkalemia.

Hard to get insurance coverage...